<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ma X</submitter><funding>Guizhou Institute of Technology High-level Talent Scientific Research Start-up Fund</funding><funding>National Outstanding Youth Science Fund Project of National Natural Science Foundation of China</funding><funding>Zunyi Technology and Big data Bureau Moutai institute Joint Science and Technology Research and Development Project</funding><pagination>24962</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11496540</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>To determine the synergistic effect and mechanism of AO/854, a new Bloom syndrome protein (BLM) helicase inhibitor, and cisplatin (CDDP), a DNA-crosslinking agent, cell viability assays, neutral comet assays, and Western blotting (WB) were performed on prostate cancer (PCa) cells. According to our findings, combining AO/854 and CDDP enhanced the antiproliferative capabilities of PC3 cell lines. As evidenced by the upregulation of γH2AX, cleaved caspase-3/caspase-3, and BAX/Bcl-2, AO/854 dramatically increased PC3 apoptosis and DNA damage induced by CDDP. Furthermore, combining AO/854 and CDDP synergistically inhibited PC3 cell migration and invasion. In addition, AO/854 inhibited CDDP-induced S-phase cell-cycle arrest in PC3 cells while enhancing G2/M-phase cell-cycle arrest. In vivo, the </pubmed_abstract><journal>Scientific reports</journal><pubmed_title>Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer.</pubmed_title><pmcid>PMC11496540</pmcid><funding_grant_id>31860242</funding_grant_id><funding_grant_id>2023GCC066</funding_grant_id><funding_grant_id>ZunaShiJiaoHe HZ zi[2020]316</funding_grant_id><pubmed_authors>Tian F</pubmed_authors><pubmed_authors>Xiao Y</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Huang M</pubmed_authors><pubmed_authors>Song D</pubmed_authors><pubmed_authors>Chen X</pubmed_authors><pubmed_authors>Xu H</pubmed_authors></additional><is_claimable>false</is_claimable><name>Synergistic effects of bloom helicase (BLM) inhibitor AO/854 with cisplatin in prostate cancer.</name><description>To determine the synergistic effect and mechanism of AO/854, a new Bloom syndrome protein (BLM) helicase inhibitor, and cisplatin (CDDP), a DNA-crosslinking agent, cell viability assays, neutral comet assays, and Western blotting (WB) were performed on prostate cancer (PCa) cells. According to our findings, combining AO/854 and CDDP enhanced the antiproliferative capabilities of PC3 cell lines. As evidenced by the upregulation of γH2AX, cleaved caspase-3/caspase-3, and BAX/Bcl-2, AO/854 dramatically increased PC3 apoptosis and DNA damage induced by CDDP. Furthermore, combining AO/854 and CDDP synergistically inhibited PC3 cell migration and invasion. In addition, AO/854 inhibited CDDP-induced S-phase cell-cycle arrest in PC3 cells while enhancing G2/M-phase cell-cycle arrest. In vivo, the </description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Oct</publication><modification>2026-06-02T21:56:39.32Z</modification><creation>2025-04-04T02:57:38.822Z</creation></dates><accession>S-EPMC11496540</accession><cross_references><pubmed>39438537</pubmed><doi>10.1038/s41598-024-75938-5</doi></cross_references></HashMap>